<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/61B18DA6-342D-4115-9BAD-6A51274BC907"><gtr:id>61B18DA6-342D-4115-9BAD-6A51274BC907</gtr:id><gtr:name>P1vital Consortium</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/61B18DA6-342D-4115-9BAD-6A51274BC907"><gtr:id>61B18DA6-342D-4115-9BAD-6A51274BC907</gtr:id><gtr:name>P1vital Consortium</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/D8C3A990-AEE2-454D-8837-A0926FC903D9"><gtr:id>D8C3A990-AEE2-454D-8837-A0926FC903D9</gtr:id><gtr:firstName>Phillip</gtr:firstName><gtr:surname>Cowen</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_U951162643"><gtr:id>50C7442D-F7C8-4CFA-9DF8-5E9CFED2E482</gtr:id><gtr:title>Clinical Psychopharmacology of 5-HT</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_U951162643</gtr:grantReference><gtr:abstractText>Clinical depression is a common illness, often beginning in early adulthood, which can recur throughout a lifetime. The recurrent nature of clinical depression, together with the burden it places on patients and their families, makes this condition one of leading medical causes of suffering and disability. Understanding the biochemical changes in the brain in depression will help us devise better treatments and also improve efforts at prevention. A neurotransmitter called serotonin (5-HT) plays an important role in both the causation of depression and in current drug treatments. In this study we will use advances in brain imaging to study how 5-HT acts in the brain to alter mood. For example we will use magnetic resonance spectroscopy (MRS) to see how 5-HT interacts with special neurons in the brain that use a chemical messenger called glutamate. We believe that the interactions between 5 HT and glutamate may be very important in helping us understand the cause of depression and in developing more effective methods of treatment. A major problem in the treatment of depression is the unpredictability of response to current drug treatments; some patients do well, others are not helped very much. We believe that antidepressants which work through 5-HT such as the selective serotonin re-uptake inhibitors (SSRIs) may produce their therapeutic effects by acting on the way the brain analyses emotional information. The use of functional magnetic resonance imaging (fMRI) allows us to examine the brain networks involved in emotional experience. We will use therefore use fMRI to study how these brain networks are influenced by SSRIs in depressed patients and whether the changes we see enable us to predict those patients who will do well with treatment.</gtr:abstractText><gtr:technicalSummary>Abnormalities in brain serotonin (5-HT) function appear to play an important role in the pathophysiology of depression and the therapeutic effects of antidepressant treatment. The present proposal builds on our previous work with ligand positron emission tomography (PET) showing that people at high risk of depression have abnormal expression of 5-HT receptors on cortical and limbic neurones. We believe that the abnormal expression of 5-HT receptors on prefrontal glutamatergic neurones leads to excessive glutamatergic feedback on 5-HT cells in the dorsal raphe, an idea we shall test using ligand PET to measure 5-HT release in this brain region. Animal experimental studies suggest that the effects of ascending 5-HT pathways on mood in depressed patients are mediated via critical interactions with glutamatergic neurones, an idea we shall translate to human studies using developments in proton magnetic resonance spectroscopy (MRS) to measure glutamate concentrations in medial prefrontal cortex in response to 5-HT manipulation. We will also assess whether effects of the NMDA receptor antagonist, ketamine, on cortical glutamate are linked to its reported antidepressant action in patients unresponsive to conventional treatments. At a neuropsychological level we believe that the effects of 5-HT on mood are exerted via modulatory actions on the neural circuitry supporting emotional experience and regulation. We will therefore use functional magnetic resonance imaging (fMRI) to test the hypothesis that the therapeutic effects of selective serotonin re-uptake inhibitors (SSRIs) in depressed patients are mediated by early positive changes in the neural processing of emotional information.</gtr:technicalSummary><gtr:fund><gtr:end>2008-03-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>1998-10-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>257698</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Cambridge</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Psychology</gtr:department><gtr:description>Wellcome Trust Inflammation Collaboration</gtr:description><gtr:id>DE90020E-9F68-4BCD-9529-2323E3AE44F2</gtr:id><gtr:impact>Application for funding to Wellcome Trust- Funded approved in Sept 2014</gtr:impact><gtr:outcomeId>p2xVsHjXPdF-1</gtr:outcomeId><gtr:partnerContribution>Expertise in immunophenotyping; access to novel therapeutic compounds</gtr:partnerContribution><gtr:piContribution>Part of a large collaboration with academe and Industry to identify the role of inflammation in depression. Our contribution is to identify the most suitable group of depressed patients and to provide patients and samples for the collaboration</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>P1vital Consortium</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>P1vital</gtr:description><gtr:id>56F04405-2A2C-4314-BBF3-638D882450B6</gtr:id><gtr:impact>Application to MRC</gtr:impact><gtr:outcomeId>WGsxzNdLriY-1</gtr:outcomeId><gtr:partnerContribution>Intellectual and financial contribution to studies of chocolate mediated reward</gtr:partnerContribution><gtr:piContribution>A MICA grant submitted to the MRC. The contribution is from J&amp;amp;J and has been brokered by P1vital</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Nuffield Department of Medicine</gtr:department><gtr:description>Oxford Biomedical Research Centre</gtr:description><gtr:id>CAA4D0A1-8021-455D-96DE-FE9A29F1A9E2</gtr:id><gtr:impact>papers submitted fro publication</gtr:impact><gtr:outcomeId>HbYPDHG5cXE-1</gtr:outcomeId><gtr:partnerContribution>provision of patients and immunological expertise</gtr:partnerContribution><gtr:piContribution>Study of the effect of interferon alpha on brain neurochemistry using MRS</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Podcast on psychiatry for University of Oxford</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>04885401-FF75-41D2-BAA6-AF3975865F20</gtr:id><gtr:impact>Enquiries about academic psychiatry career

Interest in observer placements</gtr:impact><gtr:outcomeId>545a60970cab61.83784707</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Interview for Radio in Cambridge</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>51F91F8E-119C-4C44-8776-615B6D8D1F8E</gtr:id><gtr:impact>Enquiries about future of antidepressant drug treatment

Positive feedback by email</gtr:impact><gtr:outcomeId>545a5fc122e5d6.49413724</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Podcast for BAP</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>3039C5E4-F785-4D3A-9C87-C34D1A589970</gtr:id><gtr:impact>Podcast stimulated discussion about future of psychopharmacology

request for further information</gtr:impact><gtr:outcomeId>545a60296b7a26.96101020</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>NMHB</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>ADBBC467-E4EC-4599-B323-9AC0CAF0069C</gtr:id><gtr:outcomeId>gnLHx9HFNR4</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>MRC strategic review on Mental Health Research</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>A7942C6B-B42C-437E-BB5E-7B73ECE8918F</gtr:id><gtr:outcomeId>DD500CCEC28</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>BAP guideline on depression</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>9E6EBCA5-243B-45CB-8531-631CB58E030B</gtr:id><gtr:impact>Improvement in the pharmacological management of depression</gtr:impact><gtr:outcomeId>Pq3vEe56M8g</gtr:outcomeId><gtr:type>Membership of a guidance committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>New developments in MRS analysis</gtr:description><gtr:id>78BFDB30-110D-49BF-8920-510226944413</gtr:id><gtr:impact>Papers in high impact journals. Further research funding</gtr:impact><gtr:outcomeId>TG36NDiSSCH</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>MRS development</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>1D9A7B02-3FDC-44EA-8753-1D1AD9122E26</gtr:id><gtr:title>Efficient ?-aminobutyric acid editing at 3T without macromolecule contamination: MEGA-SPECIAL.</gtr:title><gtr:parentPublicationTitle>NMR in biomedicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/edd8474b99dab84a174df456f80a5901"><gtr:id>edd8474b99dab84a174df456f80a5901</gtr:id><gtr:otherNames>Near J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0952-3480</gtr:issn><gtr:outcomeId>pm_13634_24_21387450</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E372D4EE-88E7-4612-A3CC-032E8681965B</gtr:id><gtr:title>'It's the way that you look at it'--a cognitive neuropsychological account of SSRI action in depression.</gtr:title><gtr:parentPublicationTitle>Philosophical transactions of the Royal Society of London. Series B, Biological sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9714622cbdf3aade07f0e4b795152598"><gtr:id>9714622cbdf3aade07f0e4b795152598</gtr:id><gtr:otherNames>Harmer CJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0962-8436</gtr:issn><gtr:outcomeId>pm_13634_24_23440467</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2B9285C7-0071-407D-B0AC-A947F0172E22</gtr:id><gtr:title>Effect of interferon-a on cortical glutamate in patients with hepatitis C: a proton magnetic resonance spectroscopy study.</gtr:title><gtr:parentPublicationTitle>Psychological medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/880cf52474bd701e7fe0e2f26464865f"><gtr:id>880cf52474bd701e7fe0e2f26464865f</gtr:id><gtr:otherNames>Taylor MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0033-2917</gtr:issn><gtr:outcomeId>545a573f8bee31.54146216</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D493183E-67D8-4830-99A1-5870EB6A7B9B</gtr:id><gtr:title>Neurochemistry of major depression: a study using magnetic resonance spectroscopy.</gtr:title><gtr:parentPublicationTitle>Psychopharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/08d88219fbc18330d20e7155a934dbb5"><gtr:id>08d88219fbc18330d20e7155a934dbb5</gtr:id><gtr:otherNames>Godlewska BR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0033-3158</gtr:issn><gtr:outcomeId>545a42d056c976.90817228</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BA428D22-1D13-4C6E-8823-1953F6AEC538</gtr:id><gtr:title>Frontolimbic responses to emotional faces in young people at familial risk of depression.</gtr:title><gtr:parentPublicationTitle>Journal of affective disorders</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/883e93881f45f4205fb363e9972ff32e"><gtr:id>883e93881f45f4205fb363e9972ff32e</gtr:id><gtr:otherNames>Mannie ZN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0165-0327</gtr:issn><gtr:outcomeId>pm_13634_24_20952073</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A3904093-CC98-4E08-984B-3B81F1CD8227</gtr:id><gtr:title>Early increase in marker of neuronal integrity with antidepressant treatment of major depression: 1H-magnetic resonance spectroscopy of N-acetyl-aspartate.</gtr:title><gtr:parentPublicationTitle>The international journal of neuropsychopharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/880cf52474bd701e7fe0e2f26464865f"><gtr:id>880cf52474bd701e7fe0e2f26464865f</gtr:id><gtr:otherNames>Taylor MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1461-1457</gtr:issn><gtr:outcomeId>pm_13634_24_22449253</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>62B84991-3009-4EA2-8C0A-A38DBCF4035C</gtr:id><gtr:title>Serotonin transporter polymorphisms (SLC6A4 insertion/deletion and rs25531) do not affect the availability of 5-HTT to [11C] DASB binding in the living human brain.</gtr:title><gtr:parentPublicationTitle>NeuroImage</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0dfa4fe8cf2b2b2edca20658bfa7f1f6"><gtr:id>0dfa4fe8cf2b2b2edca20658bfa7f1f6</gtr:id><gtr:otherNames>Murthy NV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1053-8119</gtr:issn><gtr:outcomeId>UTFP3jsBH6S</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EEE600BC-26C7-468B-9CF1-DB3E3E2917CE</gtr:id><gtr:title>Measuring endogenous changes in serotonergic neurotransmission in humans: a [11C]CUMI-101 PET challenge study.</gtr:title><gtr:parentPublicationTitle>Molecular psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f36a0b46d325daf7d58d5c21cdcf6fda"><gtr:id>f36a0b46d325daf7d58d5c21cdcf6fda</gtr:id><gtr:otherNames>Selvaraj S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1359-4184</gtr:issn><gtr:outcomeId>pm_13634_24_22665264</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2C310D2C-8F34-4F63-AB81-C3F5E1715157</gtr:id><gtr:title>Presynaptic Serotoninergic Regulation of Emotional Processing: A Multimodal Brain Imaging Study.</gtr:title><gtr:parentPublicationTitle>Biological psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f36a0b46d325daf7d58d5c21cdcf6fda"><gtr:id>f36a0b46d325daf7d58d5c21cdcf6fda</gtr:id><gtr:otherNames>Selvaraj S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0006-3223</gtr:issn><gtr:outcomeId>545a47bcf25172.03071933</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DCD41C0E-800D-49E2-89AB-DD9907ECFA0E</gtr:id><gtr:title>Lack of effect of ketamine on cortical glutamate and glutamine in healthy volunteers: a proton magnetic resonance spectroscopy study.</gtr:title><gtr:parentPublicationTitle>Journal of psychopharmacology (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/880cf52474bd701e7fe0e2f26464865f"><gtr:id>880cf52474bd701e7fe0e2f26464865f</gtr:id><gtr:otherNames>Taylor MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0269-8811</gtr:issn><gtr:outcomeId>pm_13634_24_21616979</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>98E729D0-AE02-4237-9BD6-7675FC19199B</gtr:id><gtr:title>SSRI administration reduces resting state functional connectivity in dorso-medial prefrontal cortex.</gtr:title><gtr:parentPublicationTitle>Molecular psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4319dfcd8ef4be50b24fbceb03f6bfac"><gtr:id>4319dfcd8ef4be50b24fbceb03f6bfac</gtr:id><gtr:otherNames>McCabe C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1359-4184</gtr:issn><gtr:outcomeId>pm_13634_24_21263442</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EEC15A91-D036-46AB-AE2A-5E9E5C00E711</gtr:id><gtr:title>Short-term antidepressant treatment and facial processing. Functional magnetic resonance imaging study.</gtr:title><gtr:parentPublicationTitle>The British journal of psychiatry : the journal of mental science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/66e098825713ff2a824ed36b33d241e9"><gtr:id>66e098825713ff2a824ed36b33d241e9</gtr:id><gtr:otherNames>Norbury R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0007-1250</gtr:issn><gtr:outcomeId>3B578A71FD9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>509DE6E1-6D2A-4D36-AC01-E8DA77BB6976</gtr:id><gtr:title>Classification of depressive disorders.</gtr:title><gtr:parentPublicationTitle>Current topics in behavioral neurosciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/657ebacd2810a554a2431b4b880d4b90"><gtr:id>657ebacd2810a554a2431b4b880d4b90</gtr:id><gtr:otherNames>Cowen PJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1866-3370</gtr:issn><gtr:outcomeId>pm_13634_24_22923074</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9E355E89-64EE-4E9E-89C2-24C7E5ED621F</gtr:id><gtr:title>A cognitive neuropsychological model of antidepressant drug action.</gtr:title><gtr:parentPublicationTitle>Progress in neuro-psychopharmacology &amp; biological psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6aeda73005ba3b506f69f4a60f8cc0ca"><gtr:id>6aeda73005ba3b506f69f4a60f8cc0ca</gtr:id><gtr:otherNames>Pringle A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0278-5846</gtr:issn><gtr:outcomeId>pm_13634_24_20673783</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B6C49979-3595-4AD0-8D3D-377445558140</gtr:id><gtr:title>Short-term SSRI treatment normalises amygdala hyperactivity in depressed patients.</gtr:title><gtr:parentPublicationTitle>Psychological medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/08d88219fbc18330d20e7155a934dbb5"><gtr:id>08d88219fbc18330d20e7155a934dbb5</gtr:id><gtr:otherNames>Godlewska BR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0033-2917</gtr:issn><gtr:outcomeId>pm_13634_24_22716999</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DF05558A-201E-4541-AFC7-33C6FF528D21</gtr:id><gtr:title>Short-term escitalopram treatment and hippocampal volume.</gtr:title><gtr:parentPublicationTitle>Psychopharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/08d88219fbc18330d20e7155a934dbb5"><gtr:id>08d88219fbc18330d20e7155a934dbb5</gtr:id><gtr:otherNames>Godlewska BR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0033-3158</gtr:issn><gtr:outcomeId>545a4520dfe3f1.13387402</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B8E6F98A-C3BA-4F91-8B8F-9BFA5B2FF785</gtr:id><gtr:title>Unedited in vivo detection and quantification of ?-aminobutyric acid in the occipital cortex using short-TE MRS at 3 T.</gtr:title><gtr:parentPublicationTitle>NMR in biomedicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/edd8474b99dab84a174df456f80a5901"><gtr:id>edd8474b99dab84a174df456f80a5901</gtr:id><gtr:otherNames>Near J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0952-3480</gtr:issn><gtr:outcomeId>DZSjnTuoNCG</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_U951162643</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>F3822669-BB5A-4BB4-BAE0-DCB9DE36E092</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Generic Health Relevance</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>